Analysis Of Antigen Processing In Melanoma Cells, Its Influence On The Success Of Cancer Vaccination And Enhancement In A Combined-immunotherapy Xenograft Model Of Melanoma
Funder
National Health and Medical Research Council
Funding Amount
$297,891.00
Summary
Cancer vaccines, an exciting new treatment option that aims to boost a patientÍs own immune system to fight a growing cancer, have shown great promise in developmental studies. Although these vaccines generate strong anti-cancer responses in the blood of treated patients, less than expected results have been observed in terms of increased patient survival. This project aims to understand how the cancer escapes recognition by the immune system and ways to enhance the effects of cancer vaccines.
Targeting The Complement Cascade: A Novel Therapeutic Strategy For Metastatic Melanoma
Funder
National Health and Medical Research Council
Funding Amount
$546,496.00
Summary
The incidence of melanoma is increasing world-wide, and Queensland has the highest rate of melanoma in the world. Despite advances in treatment, the 3-year survival rate for metastatic melanoma remains extremely low. This project builds on our recent research demonstrating a role for a key component of the innate immune system (complement C3a) in melanoma growth. Specifically we seek to investigate the potential of C3a as a therapeutic target for metastatic melanoma.
Overcoming Resistance To Cancer Immunotherapy By Targeting MET-signaling In Neutrophils
Funder
National Health and Medical Research Council
Funding Amount
$447,375.00
Summary
Cancer is a leading cause of death in Australia. The human immune system is able to attack cancer cells. However, cancer cell can escape the destruction by cytotoxic cells. The development of novel immunotherapies has revolutionized cancer therapy, but only a subgroup of patients is responding. This research project aims to identify novel combinatorial therapies blocking immune suppressive neutrophils to improve anti-cancer immunity and survival of cancer patients.
The Role Of NK Cell Receptors In Tumor Immunity And Cancer Therapy
Funder
National Health and Medical Research Council
Funding Amount
$641,264.00
Summary
White blood cells lymphocytes have an important role to play in cancer immunity and the activity of some cancer therapies. Therapeutics that improve lymphocyte function in patient tumors are showing great promise. Yet, virtually nothing is known about one family of lymphocyte receptors that control function in cancer. Using relevant mouse models of cancer and patient tumors we now wish to assess the relative importance of this family of receptors in tumor immunity, therapy, and escape.
We seek to understand how white blood cells detect and destroy disease, and how molecules of the immune system punch holes in diseased cells. We wish to learn how cancer can sometimes evade the immune system. Our work will also find out how some common treatments for cancer, like chemotherapy, can be used to boost the immune system and eliminate tumours. Through knowledge gained from these studies, we aim to develop new therapies that can help patients with devastating diseases like cancer.
Investigating The Dynamic Interactions Between Immune And Cancer Cells Using Two-photon Intravital Microscopy
Funder
National Health and Medical Research Council
Funding Amount
$401,361.00
Summary
Immune cells normally aid tumour destruction, but in some situations do the reverse and promote tumour spread. We will utilize cutting edge techniques including 2-photon microscopy together with novel transgenic mouse models to track immune cells in real time during tumour development in order to identify what factors determine a positive versus negative outcome. This will give us an unprecedented opportunity to ‘see’ how these cells interact with malignant cells which could lead to novel therap ....Immune cells normally aid tumour destruction, but in some situations do the reverse and promote tumour spread. We will utilize cutting edge techniques including 2-photon microscopy together with novel transgenic mouse models to track immune cells in real time during tumour development in order to identify what factors determine a positive versus negative outcome. This will give us an unprecedented opportunity to ‘see’ how these cells interact with malignant cells which could lead to novel therapeutic approaches.Read moreRead less
This project will investigate a new class of targeted drugs called Smac-mimetics. These drugs are proving extremely effective in promoting the death of cancer cells. Here, we aim to better understand how Smac-mimetics work as a cancer therapeutic and how they promote immune responses to cancer. This will enable us to identify combination therapies that elicit both death of the cancer cell and stimulate the immune system to promote tumour clearance.
Strategies To Enhance CD4 T Cell-mediated Anti-tumour Immunity
Funder
National Health and Medical Research Council
Funding Amount
$529,577.00
Summary
The immune system is capable of controlling cancer, but frequently does not do so. In this project we will study two factors that compromise anti-cancer immune responses: regulatory T cells, which suppress immune responses, and tolerogenic dendritic cells, which subvert potentially beneficial responses to tumours. By manipulating these factors, we hope to enhance the effectiveness of the immune response against cancer.
This Program team will discover new things about immunity to cancer and virus infection and translate the information into novel therapies in patients with blood or solid cancers. The approaches will include new cellular or antibody therapies, alone or in combination. We will determine new predictive biomarkers to better select patients for therapy. We will overcome treatment resistance, improve the safety of combination therapies, and determine their best scheduling and dosing.
This application will increase the impact of cancer immunotherapy on disease prevention and treatment, by developing new targets and novel combination immunotherapies. Outcomes will include an improved understanding of the immune reaction with cancer and more effective strategies to prevent cancer spread and safely target and eradicate a larger proportion of established and advanced malignant disease.